Evaluation of Ketamine/Midazolam Sedation vs. Fentanyl/Midazolam Sedation for Image-Guided Percutaneous Procedures in Interventional Radiology

Last updated: February 19, 2026
Sponsor: CAMC Health System
Overall Status: Active - Not Recruiting

Phase

1

Condition

Anesthesia

Treatment

Midazolam

ketamine

fentanyl

Clinical Study ID

NCT07040163
24-1149
  • Ages 18-90
  • All Genders

Study Summary

This study aims to reduce pain during interventional radiology (IR) procedures, making the experience better for patients. Typically, doctors use medications like fentanyl and midazolam for sedation. This research will focus on patients undergoing biopsies and drainage procedures, often associated with significant discomfort. Patients will be randomly assigned to receive either fentanyl/midazolam or ketamine/midazolam combinations for sedation. A coordinator will collect information on pain levels and satisfaction, as well as monitor any extra medications needed and side effects. The investigators hope to find that ketamine helps decrease pain and improves satisfaction compared to fentanyl, without increasing complications.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Planned to undergo image-guided bone biopsy, lung biopsy, or percutaneous drainage

  • Eligible to receive ketamine or fentanyl sedation

  • Any sex/gender, any race

  • Aged 18-89

Exclusion

Exclusion Criteria:

  • Pregnant/lactating

  • Incarceration

  • Currently taking an opioid agonist/antagonist

  • Food consumed in past 6-8 hours

  • Allergies to drugs used in the study

  • Lacks mental capacity for reporting pain scores

  • Hypotension or respiratory failure precluding fentanyl sedation

  • Uncontrolled hypertension precluding ketamine sedation

  • Condition for which hypertension would be a concern

  • Schizophrenia

Study Design

Total Participants: 276
Treatment Group(s): 3
Primary Treatment: Midazolam
Phase: 1
Study Start date:
March 07, 2025
Estimated Completion Date:
June 30, 2026

Study Description

This project will provide the following major innovations:

  1. Improve patient experience and satisfaction: Prospective demonstration that ketamine/midazolam results in decreased peri-procedure pain scores and increased satisfaction scores would justify the use of deep sedation in IR and potentially benefit thousands of patients undergoing painful procedures in IR units across the country.

  2. Demonstrate the safety and feasibility of ketamine/midazolam sedation administered by IR providers: Showing that performing IR procedures with ketamine/midazolam is as safe or safer than performing the same procedures with fentanyl/midazolam will increase the scope of cases that IR providers can perform without the direct assistance of anesthesia providers and need for recovery in post-anesthesia care units.

  3. Provide high level data to justify creation of societal guidelines: One barrier to IR physicians performing deep sedation may be an inability to obtain hospital privileges. Emergency medicine physicians have created societal guidelines to describe the use of deep sedation, enabling successful credentialing. Publishing high quality studies showing safety and efficacy would provide a framework for IR-specific practice guidelines.

The aims of the study are as follows:

Aim 1: Prospectively compare pain and satisfaction scores in patients undergoing IR procedures with either fentanyl/midazolam or ketamine/midazolam. Patients undergoing image-guided biopsy and drainage procedures will be randomized to receive fentanyl/midazolam or ketamine/midazolam. Patients' pain will be rated using the validated 10-point Numeric Rating Scale before, during and after the procedure, and be given questionnaires based on validated anesthesia satisfaction surveys after the procedure to assess their perception of the sedation regimen. Patient groups will be compared in terms of differences on pain scores and the satisfaction survey using two-tailed Mann-Whitney tests.

Aim 2: Prospectively compare the safety of using fentanyl/midazolam or ketamine/midazolam for sedation during IR procedures. Patient groups will be compared in terms of procedure-related adverse events (e.g., hemorrhage, pneumothorax) and sedation-related adverse events (e.g., respiratory compromise) using Fisher's exact tests.

Connect with a study center

  • CAMC Memorial

    Charleston 4801859, West Virginia 4826850 25304
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.